Literature DB >> 6277188

VP-16-213 (etoposide): the mandrake root from Issyk-Kul.

N J Vogelzang, D Raghavan, B J Kennedy.   

Abstract

VP-16-213 (etoposide) is an orally and parenterally active antineoplastic agent synthesized from podophyllum extracts of a common North American plant, the May apple or mandrake. The drug delays and kills cells in the G2 phase of the cell cycle and is active in a variety of animal tumors and leukemias. Major therapeutic activity for the drug has been found in small cell bronchogenic carcinoma, germ cell malignancies, acute non-lymphocytic leukemia, Hodgkin's disease and non-HOdgkin's lymphoma. Minor therapeutic activity of the drug occurs in non-small cell bronchogenic carcinoma, pediatric neoplasms, hepatocellular carcinoma and gastric cancer. Toxicity is primarily hematologic, with alopecia, nausea and vomiting occurring less frequently.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6277188     DOI: 10.1016/0002-9343(82)90600-3

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer.

Authors:  S Pashko; D H Johnson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

3.  Clinical trial of etoposide (VP-16) in children with recurrent malignant solid tumors. A phase II study from the Pediatric Oncology Group.

Authors:  F Kung; F A Hayes; J Krischer; D Mahoney; B Leventhal; G Brodeur; D H Berry; R Dubowy; S Toledano
Journal:  Invest New Drugs       Date:  1988-04       Impact factor: 3.850

4.  Anticancer chemotherapy.

Authors:  P Davey; G R Tudhope
Journal:  Br Med J (Clin Res Ed)       Date:  1983-07-09

5.  The effect of dose on the bioavailability of oral etoposide.

Authors:  V J Harvey; M L Slevin; S P Joel; A Johnston; P F Wrigley
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 6.  Pharmacokinetics of anticancer drugs in children.

Authors:  W R Crom; A M Glynn-Barnhart; J H Rodman; M E Teresi; R E Kavanagh; M L Christensen; M V Relling; W E Evans
Journal:  Clin Pharmacokinet       Date:  1987-03       Impact factor: 6.447

7.  Synergistic antitumor activity of vincristine and VP-16-213.

Authors:  D V Jackson; T R Long; T F Trahey; T M Morgan
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

8.  Etoposide-based combination chemotherapy in malignant histiocytosis.

Authors:  F R Lin; E G Yao
Journal:  J Tongji Med Univ       Date:  1994

9.  High throughput screening of natural products for anti-mitotic effects in MDA-MB-231 human breast carcinoma cells.

Authors:  E Mazzio; R Badisa; N Mack; S Deiab; K F A Soliman
Journal:  Phytother Res       Date:  2013-09-17       Impact factor: 5.878

Review 10.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.